Latest news and press releases about Marker Therapeutics, Inc. (MRKR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology.
Price
| Price | $1.14 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.56 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -72.42% |
| Return on Invested Capital | -76.65% |
| Return on Assets | -63.78% |
| Gross Margin | -320.83% |
| Operating Margin | -868.95% |
| Net Margin | -706.23% |
Related companies: AEON · BOLT · CLRB · COCP · EVGN · GLTO · IMNN
Explore sector: Healthcare · Biotechnology
More sections of MRKR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks